Advanced search
Publication Cover
Clinical and Experimental Hypertension Volume 41, 2019 - Issue 8
Submit an article Journal homepage
82
Views
1
CrossRef citations to date
0
Altmetric
Articles

Unique mode of binding between angiotensin II type 1 receptor and its blockers

Yoshino MatsuoDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
,
Yasunori SuematsuDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
,
Sayo TomitaDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
,
Kohei TashiroDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
,
Takashi KuwanoDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
,
Ken KitajimaDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, JapanView further author information
&
Shin-ichiro MiuraDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan;Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, JapanCorrespondence[email protected]
View further author information
 show all
Pages 747-752 | Received 27 Aug 2018, Accepted 24 Oct 2018, Published online: 19 Nov 2018

References

  • De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol Rev. 2000;52:415–72.
  • Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1–7. doi:10.1177/1470320310370852.
  • Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des. 2013;19:3002–08.
  • Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35:552–58. doi:10.1038/hr.2012.8.
  • Miura S, Matsuo Y, Nakayama A, Tomita S, Suematsu Y, Saku K. Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst. 2014;15:7–12. doi:10.1177/1470320313482170.
  • Kiya Y, Miura S, Matsuo Y, Karnik SS, Saku K. Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst. 2012;13:76–83. doi:10.1177/1470320311417478.
  • Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsepin NA, James D, Wang D, Nelson G, Weierstall U, et al. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell. 2015;161:1–12.
  • Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, Tomita S, Uehara Y, Karnik SS, Yanagisawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006;281:19288–95.
  • Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res. 2013;36:134–39. doi:10.1038/hr.2012.147.
  • Miura S, Imaizumi S, Saku K. Recent progress in molecular mechanisms of angiotensin II type 1 and 2 receptors. Curr Pharm Des. 2013;19:2981–87.
  • Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, Thomas WG. International union of basic and clinical pharmacology. XCIX. angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]. Pharmacol Rev. 2015;67:754–819. doi:10.1124/pr.114.010454.
  • White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413–20. doi:10.1161/HYPERTENSIONAHA.110.163402.
  • Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13:81–88. doi:10.1111/j.1751-7176.2010.00425.x.
  • Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336:801–08.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.